Immunotherapies and Tumor Immune Microenvironment

- 0 0
147   1 month ago
CandySwift | 0 subscribers
147   1 month ago
T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen.
Please log in or register to post comments